LiGalli

LiGalli is a Dutch medical technology company specializing in the development of the MedRing, a smart, electronic vaginal ring platform designed for both diagnostics and controlled drug delivery. The platform aims to improve women's health by providing a non-invasive, long-acting alternative to oral medications and injections, featuring sensors for real-time monitoring and automated dosing. The company's lead programs focus on treating overactive bladder through the delivery of oxybutynin and supporting in-vitro fertilization (IVF) with progesterone. By integrating digital health with pharmaceutical delivery, LiGalli seeks to enhance patient compliance and therapeutic outcomes in gynecological and systemic conditions. The MedRing technology allows for personalized treatment regimens and can communicate data directly to a patient's smartphone for clinical oversight.